BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1388 related articles for article (PubMed ID: 18034780)

  • 1. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
    Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher metabolic risk with National Institutes of Health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women.
    Anaforoglu I; Algun E; Incecayir O; Ersoy K
    Metab Syndr Relat Disord; 2011 Oct; 9(5):375-80. PubMed ID: 21657888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria.
    Goverde AJ; van Koert AJ; Eijkemans MJ; Knauff EA; Westerveld HE; Fauser BC; Broekmans FJ
    Hum Reprod; 2009 Mar; 24(3):710-7. PubMed ID: 19095675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of the homeostatic model assessment calculation score for detecting metabolic deterioration in young patients with polycystic ovary syndrome.
    Fulghesu AM; Angioni S; Portoghese E; Milano F; Batetta B; Paoletti AM; Melis GB
    Fertil Steril; 2006 Aug; 86(2):398-404. PubMed ID: 16769061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
    Lankarani M; Valizadeh N; Heshmat R; Peimani M; Sohrabvand F
    Gynecol Endocrinol; 2009 Aug; 25(8):504-7. PubMed ID: 19499403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.
    Yildiz BO; Bozdag G; Yapici Z; Esinler I; Yarali H
    Hum Reprod; 2012 Oct; 27(10):3067-73. PubMed ID: 22777527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The insulin-resistant phenotype of polycystic ovary syndrome.
    Svendsen PF; Madsbad S; Nilas L
    Fertil Steril; 2010 Aug; 94(3):1052-8. PubMed ID: 19580964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome.
    Hahn S; Fingerhut A; Khomtsiv U; Khomtsiv L; Tan S; Quadbeck B; Herrmann BL; Knebel B; Müller-Wieland D; Mann K; Janssen OE
    Clin Endocrinol (Oxf); 2005 May; 62(5):573-9. PubMed ID: 15853827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
    Broekmans FJ; Knauff EA; Valkenburg O; Laven JS; Eijkemans MJ; Fauser BC
    BJOG; 2006 Oct; 113(10):1210-7. PubMed ID: 16972863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.
    March WA; Moore VM; Willson KJ; Phillips DI; Norman RJ; Davies MJ
    Hum Reprod; 2010 Feb; 25(2):544-51. PubMed ID: 19910321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study.
    Dalamaga M; Papadavid E; Basios G; Vaggopoulos V; Rigopoulos D; Kassanos D; Trakakis E
    J Am Acad Dermatol; 2013 Dec; 69(6):922-30. PubMed ID: 24120563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria.
    Shroff R; Syrop CH; Davis W; Van Voorhis BJ; Dokras A
    Fertil Steril; 2007 Nov; 88(5):1389-95. PubMed ID: 17462641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne.
    Kelekci KH; Kelekci S; Incki K; Ozdemir O; Yilmaz B
    Int J Dermatol; 2010 Jul; 49(7):775-9. PubMed ID: 20618496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women.
    Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY
    Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria.
    Kauffman RP; Baker TE; Baker VM; DiMarino P; Castracane VD
    Am J Obstet Gynecol; 2008 Jun; 198(6):670.e1-7; discussion 670.e7-10. PubMed ID: 18355776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.